A pharmaceutical company focused on developing and commercializing rare disease treatments. The company is developing an orally administered potential treatment for Niemann-Pick disease type C, as well as treatments for idiopathic hypersomnia, narcolepsy, and Ehlers-Danlos syndrome (vEDS), and markets OLPRUVA for the treatment of certain urea cycle disorders (UCDs). Delaware-based